Oravax H. pylori oral vaccine Phase II study slated for completion in third quarter -- prospectus.
ORAVAX/PASTEUR MERIEUX ORAL H. PYLORI VACCINE PHASE II COMPLETION expected during the third quarter, Oravax reports in the prospectus for a recently completed secondary offering. The UreAB vaccine entered Phase II studies in late September at the University of Maryland and the Centre Hospital Universitaire Vaudois (Lausanne, Switzerland). Cambridge, Mass.-based Oravax is developing the H. pylori vaccine in collaboration with Pasteur Merieux under a 1995 agreement.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth